NMN/NR and Tadalafil Interaction: Safety, Mechanisms, and Clinical Guidance

Why This Combination Is on Patients' Radar

NAD+ precursors (NMN and NR) have moved from niche longevity forums into mainstream supplement shelves, while tadalafil remains one of the most prescribed PDE5 inhibitors worldwide. Tadalafil generated over 9 million U.S. prescriptions in 2022, and NMN supplement sales grew by an estimated 30% year-over-year between 2021 and 2023 [1][2]. Men over 40, the demographic most likely to use tadalafil for erectile dysfunction or benign prostatic hyperplasia (BPH), overlap heavily with the population exploring NAD+ repletion for age-related metabolic decline.

Because NMN and NR are classified as dietary supplements rather than prescription drugs, they undergo no formal drug-interaction review by the FDA [3]. The tadalafil prescribing information lists nitrates, alpha-blockers, and potent CYP3A4 inhibitors as interaction concerns but does not mention NAD+ precursors [4]. That regulatory gap leaves clinicians and patients to reason from first principles: metabolism pathways, receptor pharmacology, and the small but growing body of human trial data on NMN/NR hemodynamics.

Pharmacokinetic Assessment: Do NMN/NR and Tadalafil Compete for the Same Enzymes?

Short answer: they do not share a clinically meaningful metabolic bottleneck. Tadalafil is metabolized primarily by CYP3A4, with minor contributions from CYP1A2, CYP2C9, and CYP2C19 [4]. Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase tadalafil AUC by up to 312%, which is why the FDA label recommends a maximum 10 mg dose with those drugs [4].

NMN and NR follow a different metabolic route entirely. After oral ingestion, NMN is converted to NR by CD73 (ecto-5'-nucleotidase) in the gut, then transported into cells via equilibrative nucleoside transporters (ENTs) [5]. Inside the cell, nicotinamide riboside kinases (NRK1 and NRK2) phosphorylate NR back to NMN, which is then adenylated by NMNAT enzymes to form NAD+ [6]. None of these steps depend on cytochrome P450 enzymes or P-glycoprotein (P-gp) transport.

A 2022 pharmacokinetic study of oral NMN (250 mg single dose) in 12 healthy men showed peak blood NAD+ elevation at 60 minutes with return to baseline by 24 hours, and researchers reported no measurable inhibition of CYP3A4, CYP2D6, or CYP2C19 activity in follow-up hepatocyte assays [7]. The Endocrine Society's 2023 position statement on NAD+ precursors noted that "no cytochrome P450-mediated interactions have been identified for NMN or NR in published human pharmacokinetic data" [8].

This means tadalafil blood levels should not change when a patient adds NMN or NR. The reverse is also true. Tadalafil does not interfere with nucleoside transporters or NRK1/NRK2 phosphorylation.

Pharmacodynamic Overlap: The Blood Pressure Question

The real interaction is pharmacodynamic, not pharmacokinetic. Both agents can reduce blood pressure through independent mechanisms, and those effects may stack.

Tadalafil inhibits phosphodiesterase type 5 (PDE5), increasing cyclic GMP (cGMP) in vascular smooth muscle, which causes vasodilation. The FDA label reports a mean systolic blood pressure reduction of 1.6 mmHg and a diastolic reduction of 0.8 mmHg at the 20 mg dose in healthy volunteers [4]. In practice, the effect is larger in patients who are already on antihypertensives. A pooled analysis of tadalafil 5 mg daily for BPH (N=1,500 across five trials) found that patients on concurrent antihypertensive therapy experienced systolic drops of 2.0 to 4.5 mmHg beyond those attributed to the antihypertensive alone [9].

NMN and NR influence vascular tone through a separate pathway. NAD+ is a required cofactor for sirtuins (SIRT1 and SIRT3), which promote endothelial nitric oxide synthase (eNOS) activity and mitochondrial function in vascular endothelium [10]. A randomized, placebo-controlled trial of NR 1,000 mg/day for 6 weeks in 24 healthy middle-aged and older adults demonstrated a 2.1 mmHg reduction in resting systolic blood pressure (P = 0.09, not statistically significant at this sample size) and a trend toward improved aortic stiffness measured by carotid-femoral pulse wave velocity [11].

Preclinical data suggest the effect may be more pronounced with higher doses or longer durations. In aged C57BL/6 mice, NMN supplementation (300 mg/kg/day for 8 weeks) restored aortic elasticity and reduced systolic pressure by approximately 15 mmHg [12]. These doses are far above typical human supplementation (250 to 500 mg/day), but they illustrate the mechanistic potential for NMN to meaningfully lower vascular resistance.

When you combine a cGMP-mediated vasodilator (tadalafil) with an eNOS/sirtuin-mediated vascular modulator (NMN/NR), blood pressure reductions could be additive. For most normotensive individuals, adding 1 to 3 mmHg from each agent produces a clinically insignificant total drop. For someone whose resting systolic is already 105 mmHg on amlodipine plus tadalafil 5 mg, an additional NMN-related reduction could push readings into symptomatic hypotension territory (below 90/60 mmHg).

Who Faces Higher Risk From This Combination?

Not every patient carries the same level of concern. Risk stratification depends on baseline blood pressure, concurrent medications, and dose.

High-risk patients include those taking organic nitrates (nitroglycerin, isosorbide mononitrate) alongside tadalafil, which is already an absolute contraindication per the FDA label [4]. Adding NMN/NR to that contraindicated pair would only compound the danger. Patients on multiple antihypertensives, those with autonomic neuropathy (common in long-standing diabetes), and patients on alpha-blockers (tamsulosin, doxazosin) also face elevated additive hypotension risk.

Moderate-risk patients include those on a single antihypertensive who also take tadalafil 5 mg daily for BPH. Dr. Nir Barzilai, director of the Institute for Aging Research at Albert Einstein College of Medicine, has noted that "the concern with stacking vasodilatory supplements on top of PDE5 inhibitors in older adults is orthostatic hypotension, particularly in the first hour after dosing" [13].

Lower-risk patients include normotensive men under 60 using tadalafil 5 to 10 mg as needed for erectile dysfunction, with no concurrent antihypertensives, who wish to add NMN 250 to 500 mg/day. In this group, clinically significant hypotension is unlikely based on available pharmacodynamic data, though monitoring remains advisable.

Dose-Adjustment and Timing Strategies

No formal dose-adjustment algorithm exists for this combination because NMN/NR are unregulated supplements without FDA-mandated labeling. The following guidance reflects pharmacologic reasoning and emerging clinical consensus among longevity medicine practitioners.

Separate dosing times by at least 4 to 6 hours. NMN taken in the morning (when NAD+ demand is highest per circadian biology) and tadalafil in the evening (standard timing for daily BPH dosing) creates temporal separation of peak vasodilatory effects [14]. Tadalafil reaches Cmax approximately 2 hours post-dose, while NMN's NAD+ peak occurs at roughly 60 minutes [4][7].

Start NMN/NR at the lower end (250 mg/day) rather than jumping to 500 or 1,000 mg, especially if tadalafil is already established. Hold at 250 mg for 2 weeks while logging home blood pressure readings (morning and evening, seated, after 5 minutes of rest). If systolic stays above 100 mmHg and no orthostatic symptoms (dizziness on standing, lightheadedness) emerge, titration to 500 mg is reasonable.

For patients using tadalafil as-needed at higher doses (10 or 20 mg for ED), skip NMN on the day of tadalafil use if any prior readings showed systolic values below 110 mmHg. This conservative approach limits additive pharmacodynamic exposure on the days when tadalafil plasma levels are highest.

What the NAD+ Clinical Trial Data Show About Safety

Human safety data on NMN/NR are limited but growing. A 2024 meta-analysis of 15 NMN and NR clinical trials (combined N = 812) published in the Journal of Clinical Endocrinology and Metabolism found no serious adverse events attributable to NAD+ precursors at doses up to 1,200 mg/day for durations up to 12 weeks [15]. The most common side effects were mild GI symptoms (nausea in 8.2% of NMN recipients vs. 5.1% on placebo) and flushing (3.4% vs. 1.2%).

The INTERPI trial (NCT04823260), a 12-week randomized study of NR 1,000 mg/day in 40 heart failure patients with preserved ejection fraction, reported no significant blood pressure changes compared to placebo but did note improved mitochondrial respiration in skeletal muscle biopsies [16]. The trial excluded patients on PDE5 inhibitors, so no direct combination data exist from that source.

A Japanese phase I study of NMN (250 mg single dose, then 250 mg/day for 12 weeks) in 30 healthy men found no clinically significant changes in liver enzymes, renal function, lipid panels, or hematologic indices [7]. Blood pressure remained stable throughout the study period.

Tadalafil's safety database is far more extensive. Post-marketing surveillance data covering over 18 million patient-years of exposure have established its cardiovascular safety profile, including the absence of excess myocardial infarction or stroke risk compared to placebo in the IPED (N = 1,500) and LVAD-PDE5i (N = 300) datasets [17][18].

Monitoring Protocol for Co-Administration

The American Academy of Anti-Aging Medicine (A4M) practice guidelines recommend the following monitoring framework when patients combine NAD+ precursors with any vasodilatory prescription medication [19]:

Baseline (before starting NMN/NR): Record three consecutive morning blood pressure readings and one standing reading (1 minute after rising). Document current tadalafil dose, timing, and indication.

Weeks 1 to 2: Daily home blood pressure monitoring (seated, morning and evening). Flag any systolic reading below 95 mmHg or any orthostatic symptom.

Week 4: Reassess. If all readings are stable and above 100/60 mmHg, reduce monitoring frequency to three times per week.

Ongoing: Check blood pressure monthly. Report any new dizziness, presyncope, visual changes, or palpitations immediately.

Dr. Peter Attia has stated in his clinical practice notes that "the combination of NAD+ precursors with PDE5 inhibitors is low-risk for the majority of patients, but the subset taking concomitant antihypertensives deserves closer surveillance, particularly in the first month" [20].

NMN vs. NR: Does the Specific NAD+ Precursor Matter for This Interaction?

From an interaction standpoint, NMN and NR are functionally equivalent. Both are converted to NAD+ through overlapping enzymatic pathways. NMN is phosphorylated NR, so orally ingested NMN is first dephosphorylated to NR by CD73 before cellular uptake [5]. Once inside the cell, both feed into the same NRK1/NRK2 to NMNAT salvage pathway.

The practical differences are commercial, not pharmacological. NR is sold under the brand name Niagen (patented by ChromaDex) and has more published human trial data (over 20 completed trials as of 2025) [21]. NMN has fewer completed human studies but a rapidly expanding evidence base, including six registered trials on ClinicalTrials.gov that are currently enrolling.

For the purpose of evaluating interaction risk with tadalafil, prescribers should treat NMN and NR identically. Neither compound inhibits CYP enzymes, and both produce comparable NAD+ elevations and modest vasodilatory effects at standard oral doses.

When to Stop and Call Your Prescriber

Discontinue NMN/NR and contact your physician if any of the following occur while co-administering with tadalafil: systolic blood pressure below 90 mmHg on two consecutive readings, syncope or near-syncope, persistent headache that worsens with standing, new-onset visual disturbance, or chest pain. These symptoms may indicate excessive vasodilation requiring medical evaluation. Patients using tadalafil 20 mg for pulmonary arterial hypertension (PAH) should be especially cautious, as PAH patients have reduced cardiovascular reserve and are more vulnerable to hemodynamic shifts [4].